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Expression of the bone sialoprotein (BSP) gene, a marker of bone formation, is largely restricted to cells in
mineralized tissues. Recent studies have shown that the Cbfa1 (also known as Runx2, AML-3, and PEBP2aA)
transcription factor supports commitment and differentiation of progenitor cells to hypertrophic chondrocytes
and osteoblasts. This study addresses the functional involvement of Cbfa sites in expression of the Gallus BSP
gene. Gel mobility shift analyses with nuclear extracts from ROS 17/2.8 osteoblastic cells revealed that multiple
Cbfa consensus sequences are functional Cbfa DNA binding sites. Responsiveness of the 1.2-kb Gallus BSP
promoter to Cbfa factors Cbfa1, Cbfa2, and Cbfa3 was assayed in osseous and nonosseous cells. Each of the
Cbfa factors mediated repression of the wild-type BSP promoter, in contrast to their well known activation of
various hematopoietic and skeletal phenotypic genes. Suppression of BSP by Cbfa factors was not observed in
BSP promoters in which Cbfa sites were deleted or mutated. Expression of the endogenous BSP gene in Gallus
osteoblasts was similarly downregulated by forced expression of Cbfa factors. Our data indicate that Cbfa
repression of the BSP promoter does not involve the transducin-like enhancer (TLE) proteins. Neither
coexpression of TLE1 or TLE2 nor the absence of the TLE interaction motif of Cbfa1 (amino acids 501 to 513)
influenced repressor activity. However, removal of the C terminus of Cbfa1 (amino acids 362 to 513) relieved
suppression of the BSP promoter. Our results, together with the evolutionary conservation of the seven Cbfa
sites in the Gallus and human BSP promoters, suggest that suppressor activity by Cbfa is of significant
physiologic consequence and may contribute to spatiotemporal expression of BSP during bone development.
Bone sialoprotein (BSP) is a phosphorylated and sulfated
34-kDa protein that represents one of the major noncollag-
enous, extracellular matrix (ECM) proteins associated with
mineralized tissues. In developing rat calvaria, BSP mRNA
expression is detected in osteoblasts on day 17 along with type
I collagen, osteocalcin (OC), osteonectin, and alkaline phos-
phatase. BSP expression is also found in hypertrophic chon-
drocytes (8). BSP, similar to OC, is upregulated during osteo-
blast differentiation in vitro as the ECM mineralizes. BSP
reaches peak levels slightly earlier than OC and is downregu-
lated in mature osteocytes (14, 35, 36, 39, 43). The protein is
selectively associated with clusters of needle-like crystals of
hydroxyapatite. Various in vitro studies suggest that BSP can
either promote mineral nucleation or facilitate mineral growth
(22). In other studies the functional role of this protein was
assessed by stably transfecting murine osteosarcoma cell lines
with avian forms of this gene (15). The results demonstrated
that the cell lines expressing the highest levels of BSP displayed
the greatest accumulation of calcium in the ECM, consistent
with BSP binding to hydroxyapatite (5, 12).
Regulatory elements in the BSP promoter that contribute to
its high level of transcription in osteoblasts have not been
identified. BSP promoters from several species have been
shown to contain a negative vitamin D response element (33),
an inverted TATA sequence, a YY1 motif (28), several Sp1
sites, and a homeodomain (engrailed) motif in the proximal
promoter (59), but none of these has been demonstrated to
mediate tissue-specific expression. The OC promoter, how-
ever, has provided examples of several elements that contrib-
ute to its osteoblast-specific expression. The OC box I and
homeodomain (Msx or Dlx) binding site (20, 21, 56) both
restricts and attenuates OC expression in developing osteo-
blasts. Most significantly, multiple Cbfa (core binding factor a)
sites in the various OC promoters support cell type-specific
expression, and forced expression of Cbfa factors can confer
induction of OC promoter-reporter constructs in both osseous
and nonosseous cells (1, 11, 25). Cbfa1 has been shown to be
a key regulator of osteogenic differentiation (2, 31, 42) and
regulates several osteoblast-related genes.
The Gallus BSP promoter has been sequenced (59) and
contains multiple Cbfa consensus motifs. Several important
observations prompted examination of the functionality of
these putative Cbfa sites. Firstly, the Cbfa1 null mutant re-
vealed loss of BSP expression, along with other osteoblast
phenotypic markers (31). Secondly, the similarities between
BSP and OC with respect to their high expression levels re-
stricted to mineralized tissues in vivo and in vitro suggest that
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Cbfa may be a strong enhancer of BSP expression in mature
bone cells. However, we report here a series of experimental
approaches demonstrating that Cbfa factors mediate repres-
sion of the Gallus BSP promoter in rat and Gallus osteoblasts,
as well as in nonosseous HeLa cells.
The present studies show that the Gallus BSP promoter
contains seven functional Cbfa sites that bind an osteoblast-
specific complex comprising Cbfa factors. Cbfa mediates sup-
pression of the BSP promoter by a mechanism that does not
involve interaction of the Cbfa VWRPY domain with TLE (the
human homologue of Drosophila Groucho), a known suppres-
sor of Cbfa activity. The opposing regulation of the BSP and
OC promoters by Cbfa is consistent with distinct hormonal
responses and functional properties of the proteins. More im-
portantly, these studies reveal the significance of the promoter
context of Cbfa motifs in contributing to transcriptional con-
trol.
MATERIALS AND METHODS
Cell cultures. Osteoblasts were isolated by three sequential trypsin-collage-
nase treatments of 17-day embryonic chicken (Gallus) calvaria (14). Primary
cultures of embryonic chick osteoblasts have been well characterized with respect
to their stages of differentiation and reflect bone formation in vivo. Only the cells
released during the third digest were used for experiments. Cultures were plated
and grown for 2 weeks (until confluence) in minimal essential medium supple-
mented with 10% fetal bovine serum, with medium changes every 3 days. Upon
reaching confluence, the cultures were switched to BGJb medium supplemented
with 10% fetal bovine serum. After 2 days this medium was supplemented with
10 mM b-glycerophosphate, and after an additional 2 days the medium was
supplemented with 12.5 mg of ascorbic acid per ml. This medium was considered
complete medium. All studies were carried out 3 days after switching to complete
medium. ROS 17/2.8 cells were maintained in F12 medium supplemented with
5% fetal calf serum (Life Technologies, Inc. [Gibco BRL], Grand Island, N.Y.).
HeLa cells were cultured in suspension in Joklik-modified minimal essential
medium and plated in Dulbecco modified Eagle medium with 10% fetal calf
serum for transfections.
Nuclear extracts. Nuclear extracts were prepared according to the Dignam
method (10). Briefly, 1 3 106 rat osteoblastic cells (ROS 17/2.8) or day 3 Gallus
osteoblasts were washed once with 10 ml of ice-cold phosphate-buffered saline
(PBS) and collected by centrifuging at 165 3 g for 5 min. The cell pellet was
resuspended in 400 ml of ice-cold NP-40 lysis buffer (10 mM Tris [pH 7.4], 3 mM
MgCl2, 10 mM NaCl, 0.5% NP-40) by gentle pipetting and incubated on ice for
10 min. The nuclei pellet was collected by centrifugation for 30 s and resus-
pended in 400 ml of cold hypotonic buffer (10 mM HEPES [pH 7.9], 1.5 mM
MgCl2, 10 mM KCl). The pellet was again collected by centrifugation at 4,000 3
g for 1 min, resuspended in 50 ml of ice-cold extraction buffer (20 mM HEPES
[pH 7.9], 1.5 mM MgCl2, 420 mM KCl, 0.2 mM EDTA, 20% glycerol), and
vigorously rocked in the cold room for 30 min to 1 h followed by microfuging for
5 min. Aliquots of supernatant containing nuclear proteins were quick-frozen in
a dry ice-ethanol bath and stored at 280°C. Protein concentrations were deter-
mined using a protein assay reagent (Bradford; Bio-Rad Laboratories, Hercules,
Calif.).
Oligonucleotides, probes, and EMSA. Oligonucleotides representing the wild-
type or mutant Cbfa sites in the Gallus BSP promoter are shown in Fig. 1. The
upper strands (200 ng) of the oligonucleotides were labeled with 32P for 1 h at
37°C in a 50-ml volume using T4 Polynucleotide Kinase (New England BioLabs,
Beverly, Mass.) as indicated by the manufacturer. The reaction was stopped by
heat inactivation at 65°C for 1 h. Annealing was performed by addition of a
twofold excess amount of bottom strand followed by boiling for 5 min and slow
cooling to room temperature. The unincorporated nucleotides were removed
using a quick-spin G 25 Sephadex column (Roche Molecular Biochemicals,
Indianapolis, Ind.) according to the manufacturer’s instructions. Electrophoretic
mobility shift assay (EMSA) reaction mixtures were prepared using 50 fmol of
probe, 50 mM KCl, 12 mM HEPES, 1 mM EDTA, 1 mM dithiothreitol, 12%
glycerol, 2 mg of poly(dI-dC) z poly(dI-dC) and 0 to 10 mg of nuclear protein.
After a 20-min incubation at 22°C, unlabeled double-stranded competitor oligo-
nucleotide (12.5-, 25-, 50-, and 100-fold molar excess over probe) was added to
the reaction mixtures, and aliquots were loaded onto a 4% nondenaturing poly-
acrylamide gel. The gels were electrophoresed for 1.5 h at 200 V, dried, and
exposed to film for autoradiography.
Antibodies. The affinity-purified polyclonal antibodies (a generous gift from
Scott Hiebert [38]), designated anti-Cbfa1, anti-Cbfa2, anti-Cbfa3 and anti-Cbfb,
were raised against purified peptides. Except for anti-Cbfa2 antibody, which
recognizes an epitope in the N terminus, all the antibodies recognize epitopes
within the C termini. The specificity of each antiserum has previously been
demonstrated in detail (38). Anti-Cbfa3 and Cbfa1 are specific for their respec-
tive proteins, but anti-Cbfa2 shows a slight cross-reactivity with Cbfa1. For
EMSA supershift experiments, after incubation with the DNA probes, 1 ml of
undiluted antibody (for each) was added and incubated with either probe alone
(as a negative control) or with the reaction mixtures for an additional 20 min at
37°C.
Transient transfection and CAT assay. Rat osteosarcoma (ROS 17/2.8) or
HeLa cells were plated at a density of 0.5 3 106 per ml, 24 h prior to transfection.
Cells were transfected at 50% confluency using Superfect transfection reagent
(Qiagen Inc., Valencia, Calif.). Briefly, plasmid DNA (2.5 mg of OC or BSP
promoter-chloramphenicol acetyltransferase [CAT] constructs, 0.75 mg of either
cytomegalovirus vector control or Cbfa and TLE expression plasmid and 0.1 mg
of Rous sarcoma virus luciferase construct as an internal control) was added to
100 ml of serum-free medium and mixed with 10 ml of Superfect reagent followed
by incubation for 15 min at room temperature. After the addition of 0.4 ml of
complete medium the mixture was applied to semiconfluent cultures in 35-mm-
diameter culture dishes already washed once with PBS. The cells were incubated
with the transfection mixture for 2 h at 37°C, washed with PBS, fed 2 ml of
complete medium, and then incubated at 37°C for 30 to 36 h before harvesting.
For reporter assays, cells were first washed twice with ice-cold PBS and lysed
with 300 ml of reporter lysis buffer (Promega Corp., Madison, Wis.) for 20 min
at room temperature. For CAT assay, cell lysate (50 ml) was incubated with the
reaction mixture for 5 h at 37°C. The products were separated by thin-layer
chromatography and the amount of incorporated [14C]chloramphenicol was
quantified using the Beta-scope (Betagen, Mountain View, Calif.). The data were
normalized to luciferase values used as an internal control. For luciferase assay,
cell lysate (20 ml) was mixed with luciferase assay buffer (Promega Corp.) and the
amount of light units was measured with a Monolith luminometer (Analytical
Luminescence Laboratory, San Diego, Calif.). All experiments were repeated
four to six times (n 5 6 replicates per experiment) using at least three different
DNA preparations.
Gallus osteoblasts were transfected with Lipofectamine reagent and 15 mg of
plasmid for each assay. Briefly, plasmid DNA was complexed with Lipofectamine
reagent in a 1:2 ratio (DNA to lipofectamine) for 30 min at room temperature.
Cells cultured for 3 days in complete medium were rinsed once with sterile PBS
and overlaid with DNA-lipofectamine complexes in 6 ml of Opti-MEM trans-
fection medium for a total of 5 h. The cells were subsequently rinsed in PBS, fed
fresh complete medium, and cultured until harvesting. CAT assays were per-
formed 48 h after transfection on equal aliquots of samples. CAT activity was
assayed by liquid scintillation counting (51). The pCAT control vector containing
FIG. 1. The Cbfa sites are shown in boxed areas; the dotted box
indicates a second overlapping Cbfa motif. Mutations of the ACC core
are shown in lower case and were selected (ac) to avoid generation of
a new DNA recognition motif.
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the simian virus 40 promoter and enhancer (Promega Corp.) was used in some
experiments to compare the relative activities of the various BSP promoter
segments. The final enzyme activities were expressed in counts of [14C]chloram-
phenicol converted per minute per microgram of protein.
Site-directed mutagenesis and expression constructs. The plasmid construct
containing bp 21,239 to 125 of the BSP promoter in the sense direction relative
to the CAT coding sequence in the pCAT basic vector (Promega Corp.) was
previously described (59). Nested deletions from the 59 end of the BSP promoter
were generated by PCR amplification of selected segments of the promoter from
bp 2620, 2524, or 2131 to 125 and have been previously described (58).
Site-directed mutagenesis was performed to incorporate 2-nucleotide substitu-
tions into the core binding motif (TGG) of each individual Cbfa site (Fig. 1) in
the bp 2524 Gallus BSP promoter fragment. Initially the Cbfa site 4 mutant (Fig.
9) was generated by amplifying the bp 2524 promoter fragment using the
forward primer carrying the mutation (indicated in lower case), 59TGCCTGCA
GCAATTAGAGTacTCTGACCTG39, and the reverse primer 59GCTCTAGA
GGTGCCACTGGG39. The PCR product was digested with PstI/XbaI and
cloned in similarly digested pCAT vector (Promega Corp.). For sites 3, 2, and 1
the mutant oligonucleotides used as forward and reverse primers were the same
as those used for gel shift analyses (Fig. 1). The plasmid bearing mutations in
both sites 4 and 3 was generated by using the bp 2524 mutant (site 4) promoter
as the template. The PCR product was digested with DpnI to destroy the parental
DNA, followed by transformation in XL1-Blue competent cells (Stratagene, La
Jolla, Calif.). Similar stepwise procedures were followed to generate plasmids
carrying mutations in all four Cbfa motifs. Incorporation of the substitution
mutations in all constructs was confirmed by sequencing. CMV-driven Cbfa1,
Cbfa2, and Cbfa3 expression constructs were described previously (2). The rat
OC 59 promoter fragment (bp 21, 097 to 123) fused to the CAT gene
(pOCZCAT) containing three Cbfa-responsive motifs has been reported previ-
ously (2, 25). The Cbfa1 MASN isoform expression construct was obtained from
James C. Neil (University of Glasgow, Glasgow, United Kingdom). Cbfa1DC was
generated by digesting the MRIPV isoform with ApaI to remove the part of the
cDNA encoding amino acids 362 to 513. Two synthetic oligonucleotides (59G
GGCCCTTGATAACTCGAGGAATTCTTATCAAGGGCCC39 and 59GGG
CCCTTGATAAGAATTCCTCGAGTTATCAAGGGCCC39) containing stop
codon and unique restriction sites were hybridized to generate a cassette. The
cassette was digested with ApaI and ligated into ApaI-digested pCDNA3.1-
Cbfa1.
Cbfa1D12 was constructed by digesting the MRIPV isoform with EcoRI-XbaI
to remove the part of the cDNA encoding amino acids 501 to 513, followed by
blunting and ligation. The sequences of these constructs were confirmed by the
dideoxy chain termination method. pBluescript vectors carrying TLE1 or TLE2
cDNAs were obtained from Stefano Stifani, Montreal Neurological Institute,
Montreal, Quebec, Canada. TLE1 coding region was amplified by PCR using
forward primer 59GTAATGGATCCAGTATGGGGTTCCCGCAGAGCCGG
CACCCG39 and reverse primer 59GCCATACTCGAGCTAGTAGATGACTT
CATAGACTGTAGC39. TLE2 was amplified by PCR using forward primer
59GCAGCGGATCCAGCATGGAATACCCCCAGGGAAGGCAC39 and re-
verse primer 59GCCTGGCTCGAGTCAGTAGACCACCTCATACAC39. PCR-
generated fragments of TLE1 and TLE2 were digested with BamHI-XhoI and
FIG. 2. Gallus and human BSP promoters contain seven Cbfa consensus motifs. (A) Illustration of the positions and sequences of the Cbfa1
sites relative to several conserved regulatory sequences in the Gallus BSP promoter. TATA, TATA box; VDRE, vitamin D response element; Col
II-labeled octagons, silencer motifs. (B) Comparative schematic showing the numbers and positions of Cbfa consensus sequences in human, mouse,
and rat BSP promoters (not drawn to scale).
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cloned into BamHI-XhoI-digested pCDNA3.1 vector (Invitrogen Corporation,
San Diego, Calif.). The sequences of these constructs were confirmed by the
dideoxy chain termination method.
Isolation of total cellular RNA and Northern blot analysis. Twenty-four hours
after transient transfection, cultures of Gallus osteoblasts were rinsed twice in
1 3 PBS and incubated at room temperature for 5 to 10 min in Trizol reagent
(Life Technologies, Inc. [Gibco BRL]). (1 ml per 100-mm-diameter plate). Cells
were then scraped from the plates into a microfuge tube, and 0.1 ml of 1-bromo,
3-chloropropane (Sigma, St. Louis, Mo.) was added with mixing. After centrif-
ugation at 4°C, the aqueous layer was collected and RNA was precipitated with
0.5 ml of isopropanol. The pellets were washed with 70% ethanol to remove
residual salt, briefly air dried, dissolved in diethylpyrocarbonate-treated water,
and stored at 270°C.
RNA samples (20 mg) were electrophoresed in 1% formaldehyde-agarose gels
and transferred to Hybond-N1 membrane (Amersham Pharmacia Biotech, Ar-
lington Heights, Ill.) in 20 3 SSC (1 3 SSC is 0.15 M NaCl plus 0.015 M sodium
citrate). Blots were hybridized with randomly primed (Prime-It kit; Stratagene,
La Jolla, Calif.), 32P-labeled cDNA probes for Gallus BSP at 42°C overnight. The
radiographic signal was quantitated by using a STORM Phosphorimager (Mo-
lecular Dynamics, Sunnyvale, Calif.). Blots were then stripped and reprobed for
18S rRNA. The BSP data were normalized to rRNA values for each sample.
Western blot analysis. Western blots were performed on whole-cell lysates
from HeLa and ROS 17/2.8 cells transiently transfected with Cbfa and TLE
expression plasmids. For each construct a 100-mm-diameter dish was transfected
with 10 mg of either empty vector or expression plasmid in parallel with promot-
er-reporter transfection studies. After 24 h, cells were washed with 13 PBS and
lysed directly with 200 ml of sodium dodecyl sulfate (SDS) lysis buffer (2% SDS,
10 mM dithiothreitol, 10% glycerol, 2 M urea, 1.0 mM phenylmethylsulfonyl
fluoride, 10 mM Tris-HCl, 0.002% bromphenol blue, 13 protease inhibitor
cocktail). Protein (30 mg/well) was resolved by SDS–10% polyacrylamide gel
electrophoresis and transferred to Trans-Blot membrane (Bio-Rad Laborato-
ries). The blots were incubated with 1:5,000 dilution of mouse monoclonal
horseradish peroxidase-conjugated anti-Xpress antibody (Invitrogen Corpora-
tion) to detect the epitope-tagged Cbfa1 and TLE proteins or with a 1:2,000
dilution of rabbit polyclonal anti-Cbfa2 or -Cbfa3 antibodies. The blot was
stripped and reprobed with antibody to lamin B or a-tubulin (Santa Cruz Bio-
technology, Inc., Santa Cruz, Calif.) as a control for equal sample loading.
Immunofluorescence analysis. Primary chick osteoblasts were passed after 6
days in culture onto gelatin-coated glass coverslips (0.5 3 104 cells) and pro-
cessed for in situ immunofluorescence analysis 36 h after plating. ROS 17/2.8
cells were examined 2 days after plating. Cells were rinsed twice with ice-cold
PBS and were fixed for 10 min on ice with 4% formaldehyde. After washing once
with PBS, cells were made permeable by incubation for 20 min on ice with 0.1%
Triton X-100 in PBS and then incubated at 37°C for 1 h with the appropriate
dilution (1:150) of affinity-purified polyclonal primary antibody against Cbfa1.
Cells were washed four times with 1 ml of PBSA (0.5% BSA in PBS), followed
by incubation with a 1:400 dilution of secondary antibody (fluorescein isothio-
cyanate goat anti-rabbit) for 1 h at 37°C. Excess secondary antibody was removed
by washing the cells four times with PBSA. Cells were stained with DAPI (0.1%
49, 6-diamidino-2-phenylindole, 0.1% Triton X-100 in PBSA) for 5 min on ice
followed by a single rinse with 0.1% Triton X-100 in PBSA. Finally cells were
washed twice with ice-cold PBS and were mounted using Vectashield (Vector
FIG. 3. Analysis of deletion mutants of Gallus BSP promoter in ROS 17/2.8 osteoblastic cells. (A) Schematic illustration of 59 BSP promoter
deletion constructs used in transient transfection assays. Col II-labeled octagons, silencer motifs; VDRE, vitamin D response element. (B) Assay
of BSP promoter-CAT reporter constructs in ROS 17/2.8 cells. Cells were transfected with the indicated reporter constructs. Reporter activity was
assayed 24 h after transfection and normalized for transfection efficiency (see Materials and Methods). Data are means 1 the standard errors of
the means (SEM), (n 5 18 samples); data from three independent experiments were pooled and represent multiple DNA preparations.
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Laboratories, Inc., Burlingame, Calif.). The coverslips were sealed and stored in
the dark at 220°C till microscopy. Cells were viewed in a Zeiss Axioplan2
microscope equipped with epifluorescence filters and a charge-coupled device
digital camera. Images were displayed using Metamorph software (Universal
Imaging Corporation, West Chester, Pa.) and printed directly from Powerpoint
(version 5.1).
RESULTS
Gallus BSP promoter contains functional Cbfa motifs that
bind a Cbfa1-containing complex. Figure 2 shows the locations
of seven consensus Cbfa sites within 1.3 kb of the 59 flanking
sequences of the Gallus BSP gene. The human BSP promoter
also contains seven Cbfa recognition motifs, four of which
reside within 1.4 kb of 59 flanking sequences (Fig. 2B). In the
Gallus promoter, three Cbfa motifs are distal to the vitamin D
response element from kb 21.2 to 20.8, while four sites reside
in the proximal promoter from kb 20.5 to 20.3. In contrast,
promoters of the rodent species contain either one or two Cbfa
consensus sequences (3). In the present studies, we examined
the role of the Cbfa elements in transcriptional regulation of
the Gallus BSP promoter. We initially assessed which of these
Cbfa consensus sites may contribute to BSP transcription by
comparing expression of a series of promoter deletion con-
structs in osteoblasts. We observed both in rat osteoblastic
ROS 17/2.8 osteosarcoma cells (Fig. 3) and in Gallus primary
osteoblasts (data not shown) that the bp 2131 segment lacking
Cbfa motifs exhibited a higher level of basal activity than the
full-length promoter. This very proximal segment contains sev-
eral regulatory elements supporting activation (e.g., Sp1 and
TATA [29, 59]), and a homeodomain motif shown to mediate
enhancer activity of the BSP promoter [4]). Notably, deletion
of the upstream promoter segment (from bp 21244 to 2620),
which includes a silencer motif and three Cbfa sites, resulted in
a threefold increase in basal promoter activity. Further dele-
tion of an AP-1 motif (to bp 2524) did not significantly change
promoter activity. However, removing the four most proximal
Cbfa sites decreased activity 44% in ROS 17/2.8 cells and 50%
in Gallus osteoblasts. We therefore focused on functional char-
acterization of the Cbfa motifs in the proximal promoter.
Nuclear extracts from osteoblastic ROS 17/2.8 cells are
known to contain a bone-specific DNA binding complex that
has been characterized in relation to the Cbfa recognition
motifs in the OC promoter (1, 13, 37). Thus, we used these
FIG. 4. Sequence-specific protein-DNA interactions at the proximal Cbfa site 2 in the Gallus BSP promoter. (A) Oligonucleotides representing
wild type (WT) and mutant (mt) sequences for each Cbfa site (Fig. 1) were incubated with increasing concentrations (0 to 10 mg) of nuclear extracts
from ROS 17/2.8 cells and examined by gel mobility shift assay Solid arrowheads indicate the formation of different specific complexes.
Cbfa-related proteins bind with sequence specificity to all four proximal BSP Cbfa motifs, but representative data are shown only for site 2. The
results of competition studies shown in panels B and C demonstrate sequence-specific protein-DNA binding complexes at the BSP Cbfa sites. (B)
WT probe was incubated with 6 mg of ROS 17/2.8 nuclear extracts and increasing concentrations (0, 12.5, 25, 50, and 1003) of either WT or mutant
(mt) oligonucleotides. (C) Lane 1, WT labeled probe without nuclear extract; lane 2, probe with 6 mg of ROS 17/2.8 nuclear extract; lanes 3, 4,
and 5, competition with 100X unlabeled wild-type, mutant, and Cbfa consensus sequence oligonucleotides (Fig. 1), respectively. Only the portion
of the gel containing the complexes is shown.
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extracts to examine protein-DNA interactions at each of the
Cbfa motifs in the BSP proximal promoter. Each of these Cbfa
sites (wild type [WT]) forms a major complex that is abolished
upon mutation of the core Cbfa motif (Fig. 1 and 4A [repre-
sentative data shown for site 2]). This complex is not formed at
BSP elements using nuclear extracts from HeLa cells (data not
shown). Specificity of binding to the putative BSP Cbfa sites
was established by competition analyses with oligonucleotides
containing wild-type and mutated Cbfa sites (Fig. 4B and data
not shown), as well as the Cbfa consensus motif (Fig. 4C).
Nuclear extracts from Gallus osteoblasts also formed Cbfa
sequence-specific DNA binding complexes at the four Cbfa
sites (data not shown). Together, these analyses confirm that
each of the Cbfa motifs is a functional Cbfa interaction ele-
ment.
We identified the Cbfa factors involved in complex forma-
tion with BSP regulatory elements by antibody supershift anal-
ysis using nuclear extracts from ROS 17/2.8 cells. A panel of
well characterized, affinity-purified antibodies to the family of
Cbfa proteins encoded by distinct genes, Cbfa1, Cbfa2, and
Cbfa3 and their non-DNA binding partner, Cbfb, was used.
Figure 5 reveals a complete supershift by the Cbfa1 antibody,
as well as a partial supershift with the Cbfa2 antibody which
may reflect possible cross-reactivity with Cbfa1 (see Materials
and Methods). Cbfb, a partner protein which enhances Cbfa
DNA binding, is also present in the complexes formed at all
sites. Additionally, a very weak supershift was detected only on
sites 1 and 3 of the BSP promoter with the Cbfa3 antibody.
Thus, Cbfa1 is the major component of an osteoblast-derived
complex formed on BSP Cbfa motifs, similar to findings for the
OC promoter (2, 37).
We further confirmed the representation of Cbfa1 in Gallus
osteoblasts compared to that in rat osteoblastic ROS 17/2.8
cells by in situ immunofluorescence (Fig. 6). In the ROS 17/2.8
cells, Cbfa1 is predominantly restricted to the nucleus and
excluded from nucleoli (Fig. 6A). Cbfa1 is also detected at
significant levels in the primary (day 3) Gallus osteoblasts (Fig.
6B and C) by in situ immunofluorescence. The subnuclear
distribution of Cbfa1 in Gallus osteoblasts (Fig. 6D to F) is
shown at higher magnification. The punctate staining typical of
the nuclear matrix association of Cbfa factors is observable (54,
61). Together, these data indicate that Cbfa1 is the major
factor in osteoblasts interacting with the multiple Cbfa motifs
in the BSP proximal promoter.
Cbfa factors downregulate BSP promoter activity and ex-
pression of the endogenous gene. Cbfa1, Cbfa2, and Cbfa3
were previously documented to support enhanced transcrip-
tional activity of the rat OC promoter in both nonosseous cells
(1, 11) and the ROS 17/2.8 cell line (2). To assess the conse-
quences of Cbfa protein interactions with Cbfa elements in the
Gallus BSP promoter, we transfected the various promoter
deletion constructs (from kb 21.2 to 20.1) along with expres-
FIG. 5. Cbfa1 is the major component of the transcription factor complex binding to all BSP Cbfa sites. Electrophoretic mobility antibody
supershift analyses are shown for BSP Cbfa sites 1 to 4. Lanes 1 to 5, antibody controls for each site without nuclear extract, indicating that antisera
alone do not react with the probe; lane 6, 6 mg of nuclear extract without antibodies (control); lanes 7 to 10, the supershifts of the Cbfa complex
with the indicated antibody. A nearly complete supershift is observed in the presence of antibody specific to Cbfa1 with the complex formed by
ROS nuclear extracts at the four proximal sites (1, 2, 3, and 4) in the Gallus BSP promoter. Weak supershifts occurred using antibodies specific
to Cbfa2 and Cbfb, a transactivator partner protein for Cbfa factors.
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sion plasmids encoding each of the Cbfa proteins into either
primary Gallus osteoblasts, ROS 17/2.8 cells, or human HeLa
cells, the latter having a zero background of Cbfa factors. As
shown in Fig. 7 for the kb 21.2 Gallus BSP promoter, forced
expression of the Cbfa factors resulted in suppression of pro-
moter activity in each of the cell types. In the species-homol-
ogous Gallus osteoblasts, a highly significant 14.5- to 32-fold
suppression was observed with the three Cbfa proteins (Fig.
7A). Notably, in the mammalian cell lines, a greater suppres-
sion of the BSP promoter was observed with Cbfa3 than with
other family members (Fig. 7B and C). This finding was not the
result of significant differences in expression levels, as deter-
mined by Western blot analysis of cell layers (Fig. 7C and data
not shown). Because of the relatively weaker suppression ex-
hibited by Cbfa1 (MRIPV isoform) on the BSP promoter in
HeLa and osteoblast cells, we examined the activity of the
bone-related Cbfa1 MASN isoform (52). Only a slightly stron-
ger repression was observed for Cbfa1 (MASN) with all pro-
moter segments in osseous and nonosseous cells (Table 1).
Thus, all Cbfa factors and the two Cbfa1 isoforms regulate
suppression of BSP promoter activity.
Because the full-length promoter in HeLa and ROS 17/2.8
cells exhibited weaker suppression than in Gallus osteoblasts,
we examined Cbfa responsiveness of the bp 2620 and 2524
promoter deletions which are expressed at higher basal levels
and each contain four Cbfa sites (Table 1). The bp 2620
promoter construct contains an AP-1 site, which has been
deleted from the bp 2524 construct. The comparison of these
promoters was viewed as necessary since AP-1 proteins can
strongly regulate bone-related genes (e.g., those for OC and
collagenase 3) and can interact with Cbfa factors (49). The
deletion of the AP-1 motif does not influence this suppression.
We observe a significant level of repression by Cbfa1 in these
shorter segments (from two- to threefold in the kb 21.2 BSP
promoter to seven- to eight fold in the bp 2620 and 2524,
promoter fragments). Complete loss of repression was ob-
served with the bp 2131 promoter which lacks Cbfa motifs. A
representative example of an autoradiogram demonstrating
FIG. 6. Immunofluorescence detection of Cbfa1 in osteoblasts. (A) Cellular representation of Cbfa1 in ROS 17/2.8 cells 24 h after plating. (B)
Cellular representation of Cbfa1 in day 3 Gallus osteoblasts by immunofluorescence microscopy. Magnification, 340. Nuclear staining is observed
in whole cells incubated with antisera specific to Cbfa1 (as described in Materials and Methods). (C) Corresponding phase-contrast images of the
Gallus osteoblast cell layer. (D) Punctate subnuclear distribution of Cbfa1 foci in Gallus osteoblasts. Magnification, 3100. DAPI-stained nuclei.
(F) Differential interference contrast (DIC) of the immunopositive cells.
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the extent of suppression is shown in Figure 8. In the mam-
malian cells, we consistently observed a greater fold suppres-
sion of the proximal promoter bp 2620 and 2524 by Cbfa3
and Cbfa2 (from 8- to 16-fold) than by Cbfa1 (four- to eight-
fold). These differences were observed at several concentra-
tions of expression plasmid (data not shown), are independent
of the cell type, and are not a consequence of differences in
expression levels, as confirmed by Western blot analysis (Fig.
7C and data not shown). In the same experiment, the kb 21.1
rat OC promoter was similarly examined and the expected
upregulation occurred with all three Cbfa expression plasmids
(data not shown), ranging from four- to sixfold, as previously
reported (2).
In order to establish that suppression of BSP promoter ac-
tivity is indeed mediated by Cbfa sites, we introduced point
mutations (Fig. 1) in each of the four Cbfa sites in the bp 2524
promoter (Fig. 9). Interestingly, we observed a twofold in-
crease in basal promoter activity of the mutant promoter (Fig.
9B) and a loss of suppressor activity in response to Cbfa factors
(Fig. 9C). These results further confirm the role of Cbfa sites
in mediating repressive activity on the BSP promoter. Because
suppression of BSP by Cbfa proteins was not anticipated, we
examined the effect of Cbfa factors on the expression of the
endogenous BSP gene. Gallus primary osteoblasts were tran-
siently transfected with either empty vector or Cbfa expression
constructs, and total cellular RNA was isolated 24 h posttrans-
fection. Figure 9D shows a 31 to 39% decrease in BSP mRNA
levels in osteoblasts in response to forced expression of Cbfa
factors. This decrease in BSP expression, observed in a tran-
sient assay, defines the physiological significance of Cbfa sup-
pression of the BSP promoter in osteoblasts.
Cbfa suppression of the BSP promoter is not mediated
through Cbfa interactions with the known repressor protein
partner TLE. Drosophila Groucho and the related human TLE
FIG. 7. Cbfa factors mediate suppression of the Gallus BSP promoter containing seven Cbfa regulatory elements. Various regulatory elements
are shown in the diagram at the top of the figure. Gallus (A), ROS 17/2.8 (B), and HeLa (C) cells were transiently transfected with 2.5 mg of 21244
BSP-CAT and 0.75 mg of Cbfa1 (MRIPV), Cbfa1 (MASN), Cbfa2, or Cbfa3 as indicated. CAT activity was quantitated and normalized for
transfection efficiency. The data are fold repression values (Cbfa over empty vector). Each bar represents a pool of samples (n 5 18) from three
independent experiments. Each group showed significant repression (P , 0.001) as tested by analysis of variance. (ANOVA) HeLa cells
(100-mm-diameter dishes) were transiently transfected with 10 mg of indicated plasmid. Thirty micrograms of total protein was subjected to
SDS–10% PAGE. Blots were incubated with either mouse monoclonal Xpress antibody (to detect tagged Cbfa1 proteins) or rabbit polyclonal
anti-Cbfa2 and -Cbfa3 antibodies (see Materials and Methods). Blots were stripped and probed with a-tubulin for equal loading control. The
relative mobility of different proteins is indicated. Col II-labeled octagons, silencer motifs; VDRE, vitamin D response element.
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proteins (TLE1 and TLE2) (53) are well characterized repres-
sors of Cbfa-dependent transcription. The mechanism of this
suppression involves a specific protein-protein interaction be-
tween TLE proteins and the VWRPY motif in the C terminus
of all Cbfa factors. Earlier studies of the OC promoter dem-
onstrated that TLE suppresses Cbfa-mediated transactivation
of the OC promoter (18, 55). We anticipated that contransfec-
tion of the Cbfa factors with TLE proteins might lead to fur-
ther suppression or potentially relieve the downregulation of
promoter activity by Cbfa. TLE expression plasmids at several
concentrations had no effect on activity of the full-length or
proximal BSP promoters (data not shown). The effects of
forced Cbfa expression in the presence or absence of TLE1 or
TLE2 expression on the bp 2620 BSP promoter are shown in
Figure 10A. The fold suppression mediated by Cbfa factors or
Cbfa1 isoforms was not altered by the presence of TLE pro-
teins. Similar results were obtained using the full-length kb
21.2 promoter in osseous and nonosseous cell lines (data not
shown). These observations suggested that cellular levels of
TLE proteins may be sufficient to provide maximal suppressor
activity of Cbfa on the BSP promoter or that suppression is
independent of TLE interactions with Cbfa.
To address these possibilities, we constructed a series of
C-terminal deletion mutations of Cbfa1. The Cbfa1D12 expres-
sion construct produces a protein that lacks the last 12 amino
acids including the conserved VWRPY motif that interacts
with TLE proteins. Figure 10B shows that suppressive activity
on the BSP promoter by Cbfa1D12 is equivalent to that of the
wild-type Cbfa1 and that the coexpression of either TLE1 or
TLE2 has no effect on this suppression. These results indicate
that repression of the BSP promoter by Cbfa1 does not involve
TLE interaction. Since the Cbfa1D12 exhibited equivalent sup-
pressive activity to (WT)Cbfa1, the repressor activity must
reside in another domain of the protein. The C termini of Cbfa
factors contain several functional domains, including a 31-
amino-acid sequence that is required for trafficking these nu-
clear factors to subnuclear sites that support transcription (61).
Thus, we compared the effect of WT Cbfa1 (from amino acids
1 to 513) and Cbfa1DC (from amino acids 1 to 361), lacking the
C terminus, on BSP promoter activity. Although DNA binding
TABLE 1. Summary of repressor effects of Cbfa factors on various segments of the Gallus BSP promoter
Construct





2.1 6 0.2 1.7 6 0.2 2.7 6 0.3 4.7 6 0.2 HeLa
3.4 6 0.4 2.4 6 0.3 3.8 6 0.4 5.8 6 0.6 ROS 17/2.8
6.8 6 0.8 4.0 6 0.5 7.9 6 1.0 11.0 6 1.5 HeLa
7.4 6 1.2 4.9 6 0.5 10.4 6 1.1 14.3 6 1.3 ROS 17/2.8
6.9 6 0.8 3.9 6 0.6 9.9 6 1.1 13.2 6 1.7 HeLa
8.4 6 1.3 5.5 6 0.7 10.8 6 1.9 16.0 6 2.4 ROS 17/2.8
1.0 6 0.1 1.6 6 0.3 1.6 6 0.2 1.3 6 0.2 HeLa
1.0 6 0.1 1.3 6 0.1 1.5 6 0.1 1.7 6 0.3 ROS 17/2.8
1.0 6 0.1 1.2 6 0.2 1.2 6 0.2 1.0 6 0.2 HeLa
1.2 6 0.1 1.1 6 0.1 1.4 6 0.2 1.1 6 0.1 ROS 17/2.8
a Values shown are normalized CAT activity expressed as fold suppression. n 5 18 samples per group for each cell line.
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activity is retained, this mutant protein is not targeted to the
nuclear matrix (54). Interestingly, we observed a loss of sup-
pressor function by this mutant protein on BSP promoter ac-
tivity (Fig. 10C). Taken together, these results indicate that
BSP promoter activity and expression (mRNA) in osteoblasts
is downregulated by Cbfa1 interaction with Cbfa motifs, but
does not involve Cbfa-TLE protein-protein interactions. A dif-
ferent domain in Cbfa1, residing between amino acids 362 and
501, may contribute to Cbfa-mediated suppression of BSP pro-
moter activity.
DISCUSSION
The present studies clearly demonstrate, by several lines of
evidence, that the Cbfa family of transcription factors mediate
suppression of the Gallus BSP promoter in osseous and non-
osseous cell lines. This repression occurred in rodent and hu-
man cells (2- to 16-fold) but was most evident (14- to 32-fold)
in the species homologous Gallus osteoblasts. Notably, the
mouse BSP promoter has been characterized with respect to its
responsiveness to Cbfa1 and no consensus Cbfa sequences
were defined within the proximal 1.2 kb, nor could the pro-
moter be modulated by forced expression of Cbfa (3). The
mouse and rat share similar promoter organizational proper-
ties and are in contrast to Gallus and humans, which are more
closely related. Thus, downregulation of BSP by Cbfa appears
to be more important for regulation in humans and Gallus than
for that in rodent species, but the reason why is not clear.
Cbfa factors have been reported to mediate activation of
genes related to differentiation of either hematopoietic cells
(T- and B-cell differentiation) or osteoblasts, for example, the
mouse germ line alpha immunoglobulin promoter (50) and OC
promoters (1). Presently, a few gene promoters are known to
be downregulated by Cbfa factors (p21 and the multidrug re-
sistance [MDR] genes [34]). However, the suppressive effects
on promoter activity were observed only in certain cell types
and are either mSin3A- or TLE-dependent (24, 34). In con-
trast to those studies, we show that suppression of BSP is cell
type independent and that both the promoter and endogenous
transcripts are downregulated by Cbfa factors. Furthermore,
the suppression mechanism does not involve the interaction of
TLE proteins. Our findings, which indicate that the seven Cbfa
consensus sequences within 1.2 kb of the Gallus BSP promoter
mediate a repression of BSP transcription concurrent with the
activation of OC in osteoblasts, can be summarized as follows:
(i) deletion of 600 bp of distal BSP promoter sequences (from
kb 21.2 to 20.6) containing three Cbfa sites raises promoter
activity three- to fourfold in osteoblasts and HeLa cells, (ii)
forced expression of Cbfa factors in HeLa cells and in rat and
Gallus osteoblasts leads to marked downregulation of BSP
promoter activity and mRNA levels (31 to 39%) of the BSP
gene in osteoblasts, (iii) mutation of Cbfa motifs (bp 2524)
increases (twofold) basal promoter activity and loss of repres-
sion in response to forced expression of Cbfa factors, (iv)
competition studies and antibody supershift analyses demon-
strate sequence-specific binding of Cbfa factors to the consen-
sus regulatory elements, and, lastly, (v) deletion of the estab-
lished interaction domain of Cbfa1 with TLE does not affect
repressor activity (in contrast, deletion of the entire Cbfa1 C
terminus [amino acids 362 to 513] results in loss of suppressor
function, suggesting that other regulatory sequences are re-
quired for activity). These observations raise several significant
questions related to the biology of regulation of this bone-
restricted marker of osteoblast differentiation by the Cbfa pro-
teins, as well as the precise molecular mechanism for repressor
activity in osteoblasts involving Cbfa1.
The first question raised by our observations is the apparent
inconsistency between Cbfa repressor activity on the BSP pro-
moter and the role of Cbfa1 as a critical determinant of osteo-
genesis and osteoblast differentiation in vivo. Similar to the
bone-specific OC gene, BSP mRNA is upregulated in concert
with the active deposition of minerals (36, 41, 43, 45, 57).
However, BSP is temporally expressed earlier than OC during
development of the osteoblast phenotype and is downregu-
lated in mature osteocytes (8, 23, 35, 57, 60). Cbfa1 DNA
binding activity is highest in mature osteoblasts (2), when the
decline in BSP mRNA is observed (57). This contrasting reg-
ulation between the BSP and OC promoters by Cbfa is con-
sistent with other findings. Notably, BSP and OC are quite
distinct with respect to their tissue-specific functions and hor-
monal regulation of expression. For example, vitamin D, dexa-
methasone, and transforming growth factor b (TGF-b) have
opposing effects on transcription of these two genes. BSP is an
RGD-containing phosphorylated sialoprotein (5, 17, 40, 60).
RGD-containing bone-related proteins (9, 16, 17, 39) have
been of considerable interest because they have been shown to
interact specifically with the integrin isotypes found on oste-
oclasts (46, 47). As such, these molecules may be important in
the processes of resorption, and, therefore, BSP may require
well-controlled transcriptional levels in mature osteoblasts
possessing high levels of Cbfa1 in order for bone resorption to
be tightly regulated. In this regard, vitamin D, which can pro-
mote bone turnover and is a strong enhancer of the OC gene,
FIG. 8. Representative CAT autoradiogram of Cbfa-mediated sup-
pression of the BSP promoter. ROS 17/2.8 cells were transiently trans-
fected with 2620 BSP-CAT containing four Cbfa binding sites (upper
panel) and 2131 BSP-CAT lacking Cbfa sites (lower panel) and the
indicated Cbfa expression constructs. CMV, empty vectors.
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is a negative regulator of BSP. Thus, OC and BSP genes are
similar with respect to bone tissue-specific expression but are
distinct with respect to the timing of their expression, their
protein properties, their spatial distribution in the bone tissue,
and their functions. Thus, it may be necessary to differentially
regulate OC and BSP expression through a tissue-restricted
transcription factor. Cbfa factors may attenuate BSP levels at
certain stages of osteoblast differentiation to accommodate the
functional role of BSP in bone.
The question remains as to how BSP is initially activated in
osteoblasts, if not by Cbfa1. Studies have shown that Cbfa1 is
necessary but not sufficient for osteogenic differentiation (32).
For example, both BMP-2 and TGF-b can induce expression of
Cbfa1 and homeodomain proteins in the nonosseous myogenic
cell line C2C12 (6, 32), but only BMP-2 can support a change
to the osteogenic phenotype with concomitant expression of
OC and other osteoblast markers (27). Thus Cbfa1 may be
inducing or interacting with an unknown factor in response to
BMP-2 that functions as a transcriptional activator, either di-
rectly as a DNA binding protein or indirectly as a Cbfa partner
protein. BMP-2 induces homeodomain proteins (32, 44a)
which have been shown to support bone-specific BSP expres-
sion and mediate enhancer activity of the BSP promoter (4).
Both OC and BSP, as well as collagen type I expressed in bone,
have similar homeodomain binding motifs which have been
demonstrated to support tissue-restricted expression of OC
and collagen in osteoblasts (20, 48, 56).
Several mechanisms may contribute to Cbfa1 suppression of
BSP transcription. Our findings indicate that the C terminus of
Cbfa1 contains an important regulatory domain specific to
repression of the BSP promoter. The mutant CbfaDC lacking
amino acids 362 to 513 (known to interact with a variety of
FIG. 9. Cbfa proteins suppress expression of the BSP gene through interaction with Cbfa motifs. (A) Schematic representation of WT and Cbfa
mutant bp 2524 promoters. (B) ROS 17/2.8 cells were transfected with 2.5 mg of WT and Cbfa mutant bp 2524 promoter to assess basal promoter
activity. The cells were assayed for CAT-reporter activity as described in Materials and Methods. n 5 6. (C) The WT or mutant promoters were
cotransfected with 0.75 mg of empty vector, Cbfa1, Cbfa2, or Cbfa3 expression constructs in HeLa cells. The CAT activity was determined 24 h
posttransfection and normalized to RSV luciferase values used as an internal control. The fold suppression data were obtained by comparing Cbfa
to empty vector [n 5 6]. (D) Primary Gallus osteoblasts were transfected in triplicate with 15 mg of either empty vector, Cbfa2, or two isoforms
of Cbfa1. Cells were harvested 24 h later, and total RNA was isolated. A total of 20 mg of RNA was resolved and blots were hybridized with Gallus
BSP and rRNA probes. Values for each RNA were determined by radiographic analysis using the STORM Phosphorimager. The normalized
values of BSP RNA expression are shown at the bottom.
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FIG. 10.
2902 JAVED ET AL. MOL. CELL. BIOL.
partner proteins) fails to repress the BSP promoter. Thus, a
corepressor Cbfa1 interacting partner may participate in tran-
scriptional regulation within the context of BSP Cbfa motifs.
Our mutational evidence has proven that Cbfa elements can
mediate repression in the BSP promoter, in addition to the
activation function that has been shown for other promoters
(e.g., OC, TGF-b type 1 receptor, and collagenase 3). There-
fore, the context of the Cbfa sequences within a promoter must
contribute to the formation of a Cbfa regulatory complex,
mediating either repression or activation. While multimers of
the Cbfa consensus sequence fused to a reporter result in
enhancer activity (13, 55), the multiplicity of Cbfa sites noted
within various promoters (rat OC [37] and TGF-b type 1 re-
ceptor [26]) may provide one mechanism for context-depen-
dent modulation of activity through structural organization of
gene promoters. We have demonstrated for the OC gene that
the three Cbfa sites contribute to formation and maintenance
of promoter architecture (25). Cbfa factors are known to in-
teract with proteins that influence chromatin architecture (e.g.,
p300 histone acetyltransferases [30], LEF-ALY [19], and TLE
[7, 18, 44]). In the BSP promoter, if Cbfa binding facilitates
promoter architecture and chromatin structure, the binding of
Cbfa factors may result in secondary interactions allowing ac-
cessibility of potential transcription factors that suppress pro-
moter activity.
In conclusion, we have demonstrated promoter context-de-
pendent Cbfa-mediated suppression of the osteoblast-related
BSP gene by several lines of evidence. This first demonstration
of negative promoter regulation by Cbfa1 for an osteoblast-
expressed gene illustrates the necessity for precise control of
expression of a gene that is temporally and spatially restricted
in bone tissue and during development of the osteoblast phe-
notype.
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